Salt Lake City-based biotech Recursion Pharmaceuticals, which is part of the group of companies looking to use AI technology to accelerate drug development, has raised a $121 million Series C ...
KUALA LUMPUR, Oct 23 (Bernama) -- Recursion, a clinical stage TechBio company, announced the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback